We recently compiled a list of the 10 Stocks With At Least $10 Million In Insider Sales Recently. In this article, we are ...

Last week, Eli Lilly said it would cut the monthly price of its starter dose of Zepbound to $349. The U.S. drugmaker also is making larger doses available for $499 through its self-pay program.

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 25 trades. If we consider the specifics of ...

Now Novo Nordisk and Indianapolis-based rival Eli Lilly and Co. are seeking to capture the large market of consumers who purchased compounded weight-loss drugs to get lower prices. David Kim ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks Jim Cramer recently discussed. In a recent appearance on CNBC’s Squawk on ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...

(CNN) — Eli Lilly, the maker of blockbuster weight ... while the fourth will make injectable products, the Indianapolis-based drug giant said Wednesday. Trump said this month that he planned ...

Eli Lilly plans to invest $27 billion in four new pharmaceutical manufacturing facilities in the U.S., expanding its domestic production of medications across multiple therapeutic areas.

INDIANAPOLIS (WISH) — Eli Lilly and Company revealed plans for over $50 billion in investments to their domestic pharmaceutical manufacturing capabilities. Wednesday, the company announced the ...

Eli Lilly LLY.N plans to spend at least $27 billion to build four new manufacturing plants in the U.S., the drugmaker said at a Washington press conference on Wednesday, as it grapples with the ...

Eli Lilly (NYSE:LLY) shares rose for seven straight sessions, as the stock ended 1.5% higher at $915.2 on Wednesday. The U.S. pharmaceutical giant gained over 5% in the preceding six sessions.